Introduction
============

Historically, the brain has long been regarded as an immune-privileged area as a result of the presence of a blood-brain barrier (BBB) and the lack of lymphatic drainage. Researchers focused mainly on neurons or glial cells when investigating the underlying molecular mechanism of neurological disorders ([@B70]; [@B1]). However, mounting evidence highlights the importance of neuroinflammation in neurological diseases ([@B78]; [@B29]; [@B81]). In addition, the recently discovered glymphatic system and meningeal lymphatics uncovers a way for peripheral immune cells to enter the brain and communicate with resident cells ([@B16]; [@B83]). Thus, the function of peripheral immune cells in neurological diseases should motivate and be investigated by more researchers.

Natural killer T cells are unique CD1d-restricted T lymphocytes that function as a bridge between innate and adaptive immunity. Based on their TCR usage and lipid antigen specificity, NKT cells have been divided into two subpopulations, type I and type II. Both of these subpopulations recognize lipids antigens presented by CD1d ([@B5]; [@B38]; [@B64]). NKT cells account for a small percentage of lymphocytes, but have profound immunomodulatory roles in a variety of diseases, as these cells show both innate, and adaptive immunological features ([@B85]; [@B7]). Given the abundant existence of glycosphingolipids in the brain ([@B41]), we wondered whether and how NKT cells functioned in neurological diseases. In this review, we described NKT cell properties, summarized current reports on the functions of NKT cells in neurological disorders, including ischemic stroke, brain tumor, multiple sclerosis (MS), neurodegenerative disease and other neurological disorders, and discussed immunotherapeutic potential of these cells and the goals of future studies.

NKT Cell Classification and Effector Function
=============================================

Natural killer T cells are a specialized subset of T cells that express TCR and NK cell lineage markers, such as NK1.1, NKG2D, and Ly49A. There are two broad categories of NKT cells, type I, and type II. Type I NKT cells, known as invariant NKT cells (iNKT cells) typically express an invariant Vα14-Jα18 TCRα chain and a limited number of non-invariant TCRβ chains that recognize α-galactosylceramide (α-GalCer), a glycosphingolipid isolated from the marine sponge, presented by CD1d. In addition, an increasing number of endogenous antigens, such as isoglobotrihexosylceramide (iGb3) and disialoganglioside (GD3), have also been discovered. Conversely, type II NKT cells use diverse TCRα and β chains that are reactive to more broad antigens, such as glycolipids, phospholipids, and hydrophobic antigens ([@B5]; [@B38]; [@B64]; [Figure 1A](#F1){ref-type="fig"}). Genetic tools have been generated to study NKT cell development and function based on the TCR composition of type I and type II NKT cells. Vα14Jα18 transgenic mice and Jα18^−/−^ mice were used to enrich and delete type I NKT cells, respectively ([@B4]; [@B15]). In contrast to the Jα18^−/−^ mouse, CD1d^−/−^ mice lack both type I and type II NKT cells, as CD1d is essential for the positive selection of both subsets in the thymus ([@B13]). Unlike type I NKT cells, whose development and function have been well investigated, the functional role of type II NKT cells is less clear due to the lack of universal and specific staining antibodies, although these cells are more prevalent in humans than type I NKT cells are ([@B22]).

![NKT cell classification. **(A)** Properties of Type I (iNKT) and type II NKT cell (vNKT) subpopulations based on the composition of TCR. **(B)** Major subsets of iNKT cells. Transcription factors and cytokines associated with each subset are shown. T-bet, T-box transcription factor; GATA3, GATA-binding protein 3; RORγt, retinoic acid receptor-related orphan receptor-γt; PLZF, promyelocytic leukemia zinc finger protein; Bcl6, B-Cell Lymphoma 6; IFNγ, interferon-γ; IL-2, Interleukin 2.](fncel-13-00245-g001){#F1}

Natural killer T cells can quickly secrete large quantities of cytokines, such as interferon-γ (IFN-γ), IL-17, IL-4, and IL-10, which are important for the initiation and regulation of various immune responses ([@B7]). Researchers have recently described a new classification system according to the cytokines and transcription factors expressed by type I NKT cells, namely, Th1-like iNKT cell (iNKT1), Th2-like iNKT cell (iNKT2), Th17-like iNKT cell (iNKT17), and Tfh-like iNKT cell (iNKTfh) ([@B11]; [@B24]; [Figure 1B](#F1){ref-type="fig"}). The effector function of NKT cells is determined by the differentiation potential of these effector subsets induced via distinct mechanisms of activation. For example, activation with IL-12 and TLR agonists results in the production of Th1-type cytokines instead of Th2-type cytokines ([@B8]; [@B62]). In addition, different lipid antigens influence not only the magnitude but also the quality of NKT cell activation ([@B45]).

Natural killer T cells have been reported to participate in a variety of diseases, such as infection, autoimmune disease, and cancer ([@B22]). Upon infection, antigenic microbial lipids can be presented by CD1d and then lead to activation-induced cytokine production, which subsequently facilitates the recruitment and activation of other innate, and adaptive immune cells that promote bacterial or viral infection ([@B8]). Type I NKT cells have been implicated in antitumor immunity by direct or indirect ways ([@B37]). Notably, chimeric antigen receptor expressing NKT (CAR-NKT) cells and α-Galcer-type I NKT cell-based immunotherapy are being explored ([@B50]; [@B71]). During the autoimmune response, certain "self" lipid antigens are presented by antigen presenting cells, which then activate NKT cells to promote inflammatory cytokine production, and aggravate the disease ([@B96]). Despite the classical CD1d-mediated activation of NKT cells in disease progression, non-cognate interactions-related stimuli, including cytokines, damage-associated molecular patterns (DAMPs), and pathogen-associated molecular patterns (PAMPs), also contribute to NKT cell activation, which functions in many diseases ([@B79]; [@B67]). The detailed molecular mechanism of NKT cell-mediated disease development and progression requires further investigation.

NKT Cells and Neurological Diseases
===================================

NKT Cells and Ischemic Stroke
-----------------------------

Ischemic stroke is one of the leading causes of disability and mortality worldwide, and its incidence is increasing. Early reperfusion remains the effective treatment but can result in secondary damage; thus understanding and alleviating brain damage has become the focus of research ([@B68]). Typically, most studies have focused on neurons, the cells most sensitive to ischemic-induced injury ([@B3]). However, mounting evidence has elucidated the critical and diverse roles of immune cells during ischemic stroke ([@B43]; [@B10]), which may offer a novel perspective on immunotherapy for resolving this devastating condition.

Several studies have shown that type I NKT cells accumulate in the ischemic hemisphere in mice or rats by transient occlusion of the middle cerebral artery (tMCAO) ([@B34]; [@B52]). Similarly, when a cerebral ischemia model was induced by permanent occlusion of the middle cerebral artery (pMCAO), type I NKT cells were observed to infiltrate the blood and brain of induced mice at 24 and 48 h, and this infiltration occurred at an earlier time-point when α-Galcer was administered ([@B92]). The effects of NKT cells on cerebral stroke severity have also been studied. [@B92] discovered that brain water content, cerebral infarct volume, neurological deficit scores and brain edema were significantly increased at 24 h in the pMCAO plus α-Galcer group compared with the pMCAO plus vehicle group. In addition, the production of the proinflammatory cytokines TNFα and IFNγ was increased in the pMCAO plus α-Galcer group. These data suggest that activated type I NKT cells may contribute to brain infarction in cerebral ischemia. In contrast, [@B48] demonstrated that type I and type II NKT cells are probably of minor importance during the early phase of injury in a model of tMCAO by using CD1d-deficient mice. The reasons for the discrepant effects may result from different NKT cell manipulating methods and mouse models. In the study by [@B92] the function of activated type I NKT cells was examined by using a pMCAO mouse model through administration of α-Galcer, whereas in the study by [@B48] the effects of both type I NKT and type II NKT cell deficiency on brain infarction volume were tested by using a tMCAO model induced in CD1d^−/−^ mice. Further studies discriminating the role of different NKT cell subsets in ischemic stroke are needed.

Infectious complications, particularly pneumonia and urinary tract infections, were reported to be leading causes of death in ischemic stroke patients. The suppression of immune responses after brain ischemia increases the susceptibility to infections, and the underlying molecular mechanisms are largely unknown ([@B60]; [@B10]). Emerging evidence indicates that NKT cells function in stroke-induced suppression of the immune response. [@B94] discovered that NKT cell-deficient mice (CD1d^−/−^) showed a similar brain infarct size after tMCAO but were more susceptible to poststroke pulmonary infection with greater pulmonary damage, more prominent neutrophil infiltration and decreased survival rate. NKT cells showed restricted crawling and produced more Th2-type cytokines, including IL-10 and IL-5, and less Th1-type cytokines, such as IFN-γ and IL-12 after tMCAO. Selective immunomodulation of type I NKT cells with the specific activator α-Galcer or through the blockade of noradrenergic neurotransmitters protected mice from poststroke infections. The same group conducted another study by delineating the systemic immune profile of stroke patients over time. Consistent with observations in mouse models, a profound activation of type I NKT cells was observed after stroke, which positively correlated with IL-10 production in patients with stroke. The authors proposed that stroke-induced activation of type I NKT cells mediated an immunosuppressive response via the release of IL-10, rendering the patients more susceptible to infections ([@B95]). These results suggest that the modulation of NKT cell activation, especially enhanced IL-10 production, may prevent poststroke-associated infections, although other explanations of poststroke immunosuppression may exist.

NKT Cells and Multiple Sclerosis
--------------------------------

Multiple sclerosis is a chronic autoimmune disorder of the central nervous system (CNS) in young adults. The pathological hallmarks of MS are extensive demyelination and formation of inflammatory plaques in the spinal cord and brain, which causes irreversible neurological injuries ([@B27]). Although the cause of this disease is not entirely clear, autoreactive T cells are considered to be the main attackers on the CNS ([@B51]). Other immune cells, by affecting myelin-reactive T cell function, may also participate in this pathological condition ([@B40]).

Numerous studies have highlighted the important role of NKT cells during experimental autoimmune encephalomyelitis (EAE), the most commonly used mouse model of MS. Basically, these studies can be divided into two categories according to the tools used to manipulate NKT cells: genetic tools, such as NKT cell TCR-specific transgenic mice or NKT cell-deficient mice, to enrich or delete NKT cells and NKT cell ligands to trigger the activation of NKT cells. Vα14-Jα281 transgenic mice are protected from EAE in the non-diabetic (NOD) background, and this protection is conferred by an inhibited Th1 response ([@B57]). However, deletion of NKT cells exhibits conflicting effects on EAE, with some studies showing no effects ([@B80]; [@B30]) and other studies showing disease exacerbation in CD1d-deficient mice ([@B86]) and in Jα18-deficient mice ([@B30]; [@B65]; [@B20]). These contradictory observations may result from different mouse backgrounds or EAE models ([@B90]).

Similar to NKT cell enrichment or deletion, the activation of NKT cells through α-GalCer or its analog also has contrasting effects on EAE outcome. Most studies have shown that the activation of type I NKT cells with α-GalCer or its analog improved EAE outcome ([@B61]; [@B80]; [@B30]; [@B49]; [@B20]). These improvements are achieved either through indirectly enhancing the Th2 response and/or reducing the Th1 response ([@B61]; [@B80]; [@B30]) or potentiating the differentiation of immunosuppressive myeloid cell, such as regulatory dendritic cells (DCs) ([@B49]), myeloid-derived suppressor cells (MDSCs) ([@B69]), and M2 (alternatively activated) macrophages ([@B20]; [Figure 2](#F2){ref-type="fig"}). Unexpectedly, [@B72] demonstrated that high doses of α-GalCer could selectively interacted with CD1d2 expressed on memory T cells instead of activating type I NKT cells, which mainly required CD1d1 expression on APCs, and worsen EAE by directly enhancing Th17 and Th1 differentiation through phosphorylation of STAT3 and activation of NF-κB. Furthermore, another study found that coimmunization of α-GalCer with myelin antigens potentiated EAE in B10. PL mice and prevented EAE in C57BL/6 mice, while prior immunization prevented EAE in both strains. Exacerbation was mediated by promoting Th1 response, and protection was dependent on IL-4 production ([@B47]). For type II NKT cells, Jahng et al. discovered that administration of sulfatide, which is only recognized by a subset of type II NKT cells, protected mice from EAE in a CD1d-dependent manner ([@B46]). These differences may be due to different mouse backgrounds, as NKT cell populations differ greatly between strains. It is also worth considering that the differences may result from the activation magnitude and treatment time during disease. Regardless of the reason, one conclusion we draw is that the function of NKT cells on EAE mainly depends on the cytokines secreted or factors expressed by NKT cells which can further determine activation or inhibition of peripheral adaptive or innate immune cells, and eventually determine disease outcome.

![Molecular mechanisms of the NKT cell activation-mediated effects on EAE. Recognition of α-Galcer or its analog presented by CD1d leads to the activation of NKT cells which then secrete multiple cytokines such as IL-4, IL-10, and TGFβ. These cytokines further induce the generation of some immunosuppressive cells or Th1 cells to inhibit or enhance autoreactive T cell activation and eventually alleviate or promote EAE development.](fncel-13-00245-g002){#F2}

Several studies have investigated NKT cell number and function in MS patients. Some studies have reported that NKT cell number is decreased in MS patients ([@B44]; [@B89]; [@B19]). [@B66] observed an increased frequency of circulating NKT cells in MS patients, while [@B32] did not observe any difference. NKT cells also display distinct cytokine production profiles in MS patients. A study revealed that IL-4 production was increased by CD4^+^ NKT cell clones in RRMS (relapsing-remitting) patients compared to progressive MS patients and control subjects ([@B2]). Sara et al. found that NKT cells in secondary progressive MS patients displayed pro-inflammatory profiles ([@B18]). These conflicting findings may result from different forms of MS or distinct stages of disease progression. Notably, [@B82] reported the surprising finding that sulfatide from myelin or cerebrospinal fluid apoE could directly activate human, but not mouse, type I NKT cells. These findings indicate the important roles of NKT cells in MS, although the detailed molecular mechanism requires further investigation.

Several studies mentioned that the current available drugs targeting MS may exert their actions through targeting NKT cells. It was reported that a great reduction of type I NKT cells in the peripheral blood was associated with the remission state of MS ([@B2]), and patients who were orally given a low dose of corticosteroid restored the frequency of type I NKT cells ([@B75]). In addition, type 1 interferon-β (T1IFN-β), the first choice of therapy for MS, have been reported to promote the expansion and function of type I NKT cells to prevent autoimmune disease in pre-clinical models of MS ([@B35]). These studies raised the possibility that modulating NKT cell activity might be an alternative way to treat MS.

Altogether, the above findings indicate that NKT cells play diverse roles in MS owing to their cytokine production pattern in certain scenarios. However, some questions remain poorly understood. Instead of investigating how NKT cell activation triggers T cell response, it would be important to determine whether other autoreactive lipids exist in the brain that can activate NKT cells to directly attack the CNS. What are the different roles of type I and type II of NKT cells during MS initiation and progression? Resolving these questions may provide a comprehensive understanding of the effects exerted by NKT cells on MS and expand our strategies for the rational design of NKT-cell-based immunotherapies.

NKT Cells and Brain Tumors
--------------------------

Brain tumors remain one of the most serious diseases that pose a significant public health threat. Most primary brain tumors are of glial-cell origin, such as glioblastoma, astrocytomas, and oligodendrogliomas ([@B28]; [@B31]). Unlike other kinds of tumors, the treatment of brain tumors is especially difficult due to the blood brain barrier, which restricts drugs from gaining access to the tumors. Although immunotherapies have been considered an effective treatment for tumors, the translation of these strategies to brain tumors is still limited ([@B9]).

Recent approaches to harness antitumor T cell responses using antibodies of immune checkpoint inhibitors and chimeric antigen receptor (CAR)-T cell immunotherapy have yielded some success ([@B76]). However, due to the complexity of the tumor microenvironment, the application of cancer immunotherapy is limited ([@B53]). Revealing the functional properties and regulatory mechanisms of immune cells in the tumor microenvironment is critical to overcome the limitations of existing cancer immunotherapy and explore new approaches for cancer immunotherapy. NKT cells, as the bridging system between innate immunity and adaptive immunity, have been implicated in tumor recognition and destruction ([@B6]; [@B37]). Type I NKT cells target tumor cells by diverse effective strategies. First, these cells can kill tumor cells by secreting perforin and granzyme B via cytolysis ([@B63]). Second, activated type I NKT cells secrete various kinds of cytokines to modulate the function of other immune cells such as T cells, B cells and DCs. Third, immunosuppressive cells, including tumor-associated macrophages (TAMs) and MDSCs, could also be targeted by type I NKT cells to indirectly attack tumor cells ([@B59]; [@B71]). Unlike type I NKT cells, type II NKT cells have been reported to inhibit antitumor immunity, although only a few investigations into the role of type II NKT cells in cancer have been published ([@B37]).

Type I NKT cell number and functional properties have been evaluated in glioma patients. Both the number and expanding potential of type I NKT cells in the blood of glioma patients was comparable to those of healthy controls, and these cells could kill glioma in a CD1d-dependent manner, indicating their normal function ([@B21]; [@B87]). Moreover, CD1d expression has been observed in some kinds of brain tumors including medulloblastoma and glioblastoma ([@B54]; [@B71]). These results suggest that enhancing type I NKT cell function may potentiate antitumor immunity. In support of this notion, studies have observed tumor killing potential by using strategies to induce type I NKT cell activation. Vaccination with irradiated tumor cells pulsed with α-Galcer significantly induced the activation of type I NKT cells and was effective for the treatment of glioma ([@B42]). Intracranial administration of NKT cells with the α-Galcer analog 7DW8-5 resulted in an obvious anti-tumor effect ([@B54]). In addition, co-delivery of tumor-derived exosomes with α-Galcer-loaded DCs improved priming of CD8 T cells and elicited strong anti-tumor immune responses ([@B55]). To date, the function of type II NKT cells in brain tumors is not understood. These results highlight the necessity of further research to clarify the effects and molecular mechanism of NKT cell subsets in regulating brain tumor immunity, which may offer new therapeutic targets for brain tumor immunotherapy.

NKT Cells and Neurodegenerative Disease
---------------------------------------

The increased frequency of neurodegenerative disease can reduce human life expectancy. The most common neurodegenerative diseases are Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). Understanding the causes and molecular mechanisms of each disease is desperately required for the effective treatment of neurodegeneration ([@B39]; [@B36]).

Despite the well-established role of neuroinflammation in neurodegenerative disease, the function of NKT cells in neurodegeneration is limited ([@B12]). Notably, Finkelstein et al. reported the role of type I NKT cells in amyotrophic lateral sclerosis (ALS). Type I NKT cells were dramatically accumulated in the spinal cord, spleen and liver of the induced mouse ALS model. Immunomodulation of NKT cells using an analog of α-GalCer delayed motor neuron death and reduced astrogliosis in the spinal cord. Mechanistically, modulation of NKT cells induced a cytokine shift in the liver and facilitated T cell recruitment into the affected spinal cord, leading to a significant prolongation of the life span of mSOD1 mice ([@B26]). Clearly, more research is required to understand the role of NKT cells in other neurodegenerative diseases considering the high abundance of glycolipids in the brain ([@B41]).

NKT Cells and CNS Viral Infection
---------------------------------

The CNS is classically considered an immune-privileged area. The presence of pathogens can activate tissue resident immune cells via the recognition of PAMPs with pattern recognition receptors (PRRs), resulting in neuroinflammation and inducing subsequent T cell infiltration. Infection of the CNS usually generates efficient immune responses([@B73]). [@B58] demonstrated that type I NKT cells resided in the CNS in the absence of inflammation and their presence dramatically augmented after local viral infection. The infiltrating NKT cells expressed a pro-inflammatory cytokine profile and inhibited the anti-viral responses of CD8 T cells. Accordingly, treatment with exogenous type I NKT cell ligands inhibited the viral-specific CD8 T cell response. These results indicate the involvement of type I NKT cells in viral infection of the CNS.

NKT Cells and X-Linked Adrenoleukodystrophy (X-ALD)
---------------------------------------------------

X-linked adrenoleukodystrophy is a metabolic disorder with the accumulation of very long-chain fatty acids (VLCFA) in plasma and tissues caused by impaired peroxisomal beta-oxidation. The disease is characterized by progressive demyelination within the CNS and adrenal insufficiency ([@B25]). In ALD patients, type I NKT cell frequency and CD1d expression on the surface of B cells were slightly decreased ([@B33]). Considering the correlation between NKT cell activation ligands and fatty acid metabolism, the function of NKT cells in ALD progression deserves further investigation in mouse models.

NKT Cells and Myasthenia Gravis
-------------------------------

Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction that causes weakness in the skeletal muscles ([@B88]). Increased mature NKT cells were observed in the blood of MG patients with thymic hyperplasia, but not in those with thymoma ([@B84]). Immunization with α-GalCer activated type I NKT cells and protected mice from the occurrence of experimental autoimmune myasthenia gravis (EAMG), an animal model of human myasthenia gravis, which may be caused by the increased expansion of Treg cells ([@B56]; [@B91]).

NKT Cells and Neurological Antiphospholipid Syndrome (APS)
----------------------------------------------------------

Antiphospholipid syndrome is an autoimmune disorder characterized by the presence of antiphospholipid antibodies, such as anticardiolipin antibodies, anti-β2-glycoprotein 1 antibodies, and lupus anticoagulant ([@B77]). APS neurological manifestations have been reported to be associated with some neurological diseases including ischemic stroke and MS ([@B74]; [@B17]). Of note, cardiolipin is among the reported lipids antigens recognized by CD1d and this recognition may explain the increased number of NKT cells in some autoimmune diseases ([@B14]; [@B17]). [@B93] demonstrated that injection of apoptotic cells decreased the ability of type I NKT cells to produce cytokines, which further increased autoreactive B cells to produce autoreactive antibodies, such as anticardiolipin antibodies and antiphosphorylcholine, although this contrasts with the demonstration that NKT cells could promote B cell responses, and antibody production ([@B23]). Considering the close association of antiphospholipid antibodies and some neurological diseases, it will be interesting to modulate NKT cell activity to regulate APS, although a better understanding of NKT cell and APS is needed.

Conclusion
==========

Recent studies have elucidated novel and striking aspects of NKT cell function and its modulatory roles in disease progression. NKT cell-modulated neurological diseases, particularly ischemic stroke, MS and glioblastoma have been described ([Table 1](#T1){ref-type="table"}). Despite major advances in the understanding of NKT cell effector function in neurological disorders, there is still much to learn about. First, as more is learned about NKT heterogeneity, different NKT cell subsets should be discriminated in pathological conditions. There is very little knowledge of the role of type II NKT cells in neurological disease which should be the goal of future studies. Second, NKT cell function should be investigated in different disease progression stages. For ischemic stroke, NKT cells do not affect infarct volume but function in poststroke immunosuppression, which is also a very important factor that determines the life span of patients. Third, given the critical role of inflammation in neurodegenerative disease, the function of NKT cells in PD and AD should be explored. Finally, despite the well-established role of cognate recognition-induced activation of NKT cells, the non-cognate interaction-induced activation of NKT cells in disease progression deserves further investigation. If a thorough understanding of the roles and molecular mechanisms of NKT cells in neurological disease is gained, new avenues might be opened in the treatment of neurological disorders.

###### 

Direct evidence of NKT cell functions in neurological diseases.

  Neurological diseases (Mouse model)               Tools to study NKT cells                                     NKT cell subtype   Effects in pathological condition                                                                                                 References
  ------------------------------------------------- ------------------------------------------------------------ ------------------ --------------------------------------------------------------------------------------------------------------------------------- ------------------------
  Ischemic stroke                                                                                                                                                                                                                                                     
  tMCAO                                             CD1d^−/−^ mice                                               Type I and II      Do not affect infarct volume, promote post-stroke immune suppression                                                              [@B48]; [@B60]
  pMCAO                                             α-Galcer or its analog injection                             Type I             Accelerate infarct volume and brain edema                                                                                         [@B92]
  tMCAO                                             α-Galcer injection                                           Type I             Inhibit post-stroke infection                                                                                                     [@B60]
  Multiple sclerosis (EAE)                          α-Galcer or its analog injection                             Type I             Protect mice from EAE by promoting Th2 response and suppress Th1 response                                                         [@B61]; [@B80]; [@B30]
                                                    α-Galcer injection prior to or at the time of immunization   Type I             Potentiate or prevent EAE depending on mice strain and timing of activation                                                       [@B47]
                                                    α-Galcer injection (high dose)                               Type I             High dose of α-Galcer potentiate EAE by directly enhancing Th17 response                                                          [@B72]
                                                    α-Galcer injection at early phase of EAE                     Type I             Improve disease outcome by the differentiation of inflammatory monocytes to M2 macrophage                                         [@B20]
                                                    α-Galcer injection                                           Type I             Suppress EAE by inducing a regulatory DC via secretion IL-10                                                                      [@B49]
                                                    Ja18-KO mice or adoptive NKT cell transfer                   Type I             IL-4- and IL-10-producing iNKT cells inhibit the Th1 cell response and protect mice against EAE; No significant effect            [@B57]; [@B30]; [@B65]
                                                    CD1d^−/−^ mice                                               Type I and II      NKT cells protect mice from EAE by CD1-dependent enhancement of TGFβ production; No significant effect                            [@B80]; [@B30]; [@B86]
                                                    Vα14Jα281 transgenic mice                                    Type I             Increased NKT cells protect mice from EAE by inhibition of Th1 response                                                           [@B57]
                                                    Sulfatide injection                                          Type II            Prevents EAE in a CD1d-dependent manner                                                                                           [@B46]
  Brain tumor                                                                                                                                                                                                                                                         
  medulloblastoma                                   Co-injection of NKT with α-Galcer analog                     Type I             Intracranial injection of NKT resulted in regression of orthotopic MB xenografts in NOD/SCID mice                                 [@B54]
  glioma                                            α-Galcer pulse tumor cells                                   Type I             α-Galcer pulsed tumor cells stimualtes NKT cells and augment T cell response to kill tumor                                        [@B42]
  glioblastoma                                      α-Galcer pulse dendritic cells                               Type I             Co-delivery of tumor-derived exosomes with α-GalCer on a DC-based vaccine showed powerful effects in glioblastoma immunotherapy   [@B55]
  Neurodegenerative disease (ALS-SOD1G93A mice)     α-GalCer analog, PBS57 treatment                             Type I             Treatment with PBS57delayed the onset of the disease and prolonged the survival of mSOD1 mice                                     [@B26]
  CNS viral infection (Theiler's virus infection)   α-GalCer treatment, Vα14 transgenic mice, Jα18^−/−^ mice     Type I             NKT cells inhibit anti-viral CD8 T cell responsean augmented mortality during acute viral infection                               [@B73]
  Myasthenia gravis (EAMG)                          α-GalCer treatment                                           Type I             NKT cells protect mice from EAMG by increasing the expansion of Treg cells                                                        [@B56]; [@B91]
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